MISVIK BIOLOGY OY

Their core work

Misvik Biology is a Finnish SME specializing in toxicology testing and risk assessment for nanomaterials and chemicals. They develop and apply advanced biological assays, computational toxicology models, and new approach methodologies (NAMs) that help manufacturers and regulators evaluate the safety of nanomaterials without relying solely on animal testing. Their work bridges the gap between laboratory hazard data and real-world risk decisions, making them a go-to testing partner for EU nanosafety research consortia.

What they specialise in

How they've shifted over time

In their early H2020 period (2016–2018), Misvik focused on broad risk governance frameworks — control banding, hazard prediction, exposure modelling, and computational toxicology tools (caLIBRAte, PATROLS). From 2019 onward, their work became more applied and industry-facing: nanoinformatics platforms, safe-by-design for manufacturing (SABYDOMA), and precision toxicology using new approach methodologies (PrecisionTox). The trajectory shows a clear shift from risk assessment frameworks toward actionable safety tools embedded in industrial and regulatory workflows.

Misvik is moving toward regulatory-ready alternative testing methods and industry-integrated safety tools, positioning them well for the EU's growing push to replace animal testing and implement safe-by-design principles.

How they like to work

Misvik consistently joins large consortia as a specialist participant — they have never coordinated an H2020 project but have been a trusted partner in 6 projects with 106 unique consortium partners across 28 countries. This pattern suggests they are valued for specific technical capabilities (biological testing, toxicology assays) rather than project management. For potential collaborators, this means a reliable, low-overhead partner who delivers specialized work without competing for leadership roles.

With 106 unique consortium partners across 28 countries, Misvik has built a remarkably wide network for a small company — almost entirely within the European nanosafety and toxicology research community. Their network spans nearly all EU member states, reflecting the pan-European nature of nanosafety regulation.

What sets them apart

Misvik occupies a rare niche as a private SME offering specialized toxicology testing services within the European nanosafety ecosystem — most comparable expertise sits in universities or large research institutes. Their consistent participation across the major EU nanosafety projects (caLIBRAte, PATROLS, NanoSolveIT, SABYDOMA, HARMLESS, PrecisionTox) makes them one of the best-connected commercial toxicology labs in Europe for nanomaterial safety. For consortium builders, they bring industry-grade biological testing capabilities without the overhead or IP complications of a large corporate partner.

Highlights from their portfolio

• PrecisionTox
  Their largest project by far (EUR 919K) and a flagship EU initiative on next-generation chemical safety testing using evolutionary biology and NAMs.
• NanoSolveIT
  Focused on building a cloud-based nanoinformatics platform — represents Misvik's contribution to digitizing nanomaterial risk assessment at scale.
• SABYDOMA
  Bridges safety testing with industrial manufacturing through on-line screening and safe-by-design, showing Misvik's move toward applied industry solutions.